Nutrition Strategies to Improve Physical Capabilities in Duchenne Muscular Dystrophy

Physical Medicine and Rehabilitation Clinics of North America

Volumn 23, Issue 1, 2012, Pages 187-199

  Davoodi, J ^a,b   Markert, C D ^c   Voelker, K A ^a   Hutson, S M ^a   Grange, Robert W ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEHRAN   (Iran)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Duchenne muscular dystrophy; Nutraceuticals; Nutrition; Physical activity

Indexed keywords

ALANINE; ARGININE; DEFLAZACORT; EPIGALLOCATECHIN GALLATE; GLUTAMINE; GREEN TEA EXTRACT; INITIATION FACTOR 4E BINDING PROTEIN 1; LEUCINE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; NUTRACEUTICAL; PLACEBO; PREDNISOLONE; TAURINE;

ABSENCE OF SIDE EFFECTS; CLINICAL FEATURE; DIET THERAPY; DRUG MECHANISM; DUCHENNE MUSCULAR DYSTROPHY; ENERGY BALANCE; HEALTH CARE PRACTICE; HUMAN; KINESIOTHERAPY; MUSCULAR DYSTROPHY; NONHUMAN; NUTRITIONAL ASSESSMENT; NUTRITIONAL REQUIREMENT; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PHYSICAL CAPACITY; PHYSICAL MOBILITY; PHYSIOTHERAPY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; THERAPY EFFECT; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; CAMELLIA SINENSIS; DIETARY SUPPLEMENTS; HUMANS; LEUCINE; MOTOR ACTIVITY; MUSCULAR DYSTROPHY, DUCHENNE; PHYTOTHERAPY; PLANT EXTRACTS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84855732052     PISSN: 10479651     EISSN: 15581381     Source Type: Journal    
DOI: 10.1016/j.pmr.2011.11.010     Document Type: Review

References (75)

1. Durbeej M., Campbell K.P. Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models. Curr Opin Genet Dev 2002, 12(3):349-361.
2. Blake D.J., Weir A., Newey S.E., et al. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 2002, 82(2):291-329.
3. Davies K.E., Nowak K.J. Molecular mechanisms of muscular dystrophies: old and new players. Nat Rev Mol Cell Biol 2006, 7(10):762-773.
4. Ervasti J.M., Ohlendieck K., Kahl S.D., et al. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 1990, 345(6273):315-319.
5. Petrof B.J., Shrager J.B., Stedman H.H., et al. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA 1993, 90(8):3710-3714.
6. Petrof B.J. The molecular basis of activity-induced muscle injury in Duchenne muscular dystrophy. Mol Cell Biochem 1998, 179(1-2):111-123.
7. Bushby K., Finkel R., Birnkrant D.J., et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010, 9(1):77-93.
8. Davidson Z.E., Truby H. Areview of nutrition in Duchenne muscular dystrophy. JHum Nutr Diet 2009, 22(5):383-393.
9. Call J.A., Voelker K.A., Wolff A.V., et al. Endurance capacity in maturing mdx mice is markedly enhanced by combined voluntary wheel running and green tea extract. JAppl Physiol 2008, 105(3):923-932.
10. Bushby K., Finkel R., Birnkrant D.J., et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010, 9(2):177-189.
11. Ervasti J.M., Sonnemann K.J. Biology of the striated muscle dystrophin-glycoprotein complex. Int Rev Cytol 2008, 265:191-225.
12. Petrof B.J. Molecular pathophysiology of myofiber injury in deficiencies of the dystrophin-glycoprotein complex. Am J Phys Med Rehabil 2002, 81(Suppl 11):S162-S174.
13. Willmann R., De Luca A., Benatar M., et al. Enhancing translation: Guidelines for standard pre-clinical experiments in mdx mice. Neuromuscul Disord 2011, [Epub ahead of print].
14. Willmann R., Possekel S., Dubach-Powell J., et al. Mammalian animal models for Duchenne muscular dystrophy. Neuromuscul Disord 2009, 19(4):241-249.
15. Grange R.W., Call J.A. Recommendations to define exercise prescription for Duchenne muscular dystrophy. Exerc Sport Sci Rev 2007, 35(1):12-17.
16. Markert C.D., Ambrosio F., Call J.A., et al. Exercise and Duchenne muscular dystrophy: toward evidence-based exercise prescription. Muscle Nerve 2011, 43(4):464-478.
17. Hudgson P., Gardner-Medwin D., Pennington R.J., et al. Studies of the carrier state in the Duchenne type of muscular dystrophy. I. Effect of exercise on serum creatine kinase activity. JNeurol Neurosurg Psychiatry 1967, 30(5):416-419.
18. Sockolov R., Irwin B., Dressendorfer R.H., et al. Exercise performance in 6-to-11-year-old boys with Duchenne muscular dystrophy. Arch Phys Med Rehabil 1977, 58(5):195-201.
19. Levine J.A. Measurement of energy expenditure. Public Health Nutr 2005, 8(7A):1123-1132.
20. American College of Sports Medicine Position Stand. The recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness, and flexibility in healthy adults. Med Sci Sports Exerc 1998, 30(6):975-991.
21. Passaquin A.C., Renard M., Kay L., et al. Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice. Neuromuscul Disord 2002, 12(2):174-182.
22. Ruegg U.T., Nicolas-Metral V., Challet C., et al. Pharmacological control of cellular calcium handling in dystrophic skeletal muscle. Neuromuscul Disord 2002, 12(Suppl 1):S155-S161.
23. Archer J.D., Vargas C.C., Anderson J.E. Persistent and improved functional gain in mdx dystrophic mice after treatment with L-arginine and deflazacort. FASEB J 2006, 20(6):738-740.
24. Hankard R.G., Hammond D., Haymond M.W., et al. Oral glutamine slows down whole body protein breakdown in Duchenne muscular dystrophy. Pediatr Res 1998, 43(2):222-226.
25. Mok E., Eleouet-Da Violante C., Daubrosse C., et al. Oral glutamine and amino acid supplementation inhibit whole-body protein degradation in children with Duchenne muscular dystrophy. Am J Clin Nutr 2006, 83(4):823-828.
26. Radley H.G., De Luca A., Lynch G.S., et al. Duchenne muscular dystrophy: focus on pharmaceutical and nutritional interventions. Int J Biochem Cell Biol 2007, 39(3):469-477.
27. Bornman L., Rossouw H., Gericke G.S., et al. Effects of iron deprivation on the pathology and stress protein expression in murine X-linked muscular dystrophy. Biochem Pharmacol 1998, 56(6):751-757.
28. Disatnik M.H., Chamberlain J.S., Rando T.A. Dystrophin mutations predict cellular susceptibility to oxidative stress. Muscle Nerve 2000, 23(5):784-792.
29. Disatnik M.H., Dhawan J., Yu Y., et al. Evidence of oxidative stress in mdx mouse muscle: studies of the pre-necrotic state. JNeurol Sci 1998, 161(1):77-84.
30. Murphy M.E., Kehrer J.P. Free radicals: a potential pathogenic mechanism in inherited muscular dystrophy. Life Sci 1986, 39(24):2271-2278.
31. Ragusa R.J., Chow C.K., Porter J.D. Oxidative stress as a potential pathogenic mechanism in an animal model of Duchenne muscular dystrophy. Neuromuscul Disord 1997, 7(6-7):379-386.
32. Rando T.A., Disatnik M.H., Yu Y., et al. Muscle cells from mdx mice have an increased susceptibility to oxidative stress. Neuromuscul Disord 1998, 8(1):14-21.
33. Buetler T.M., Renard M., Offord E.A., et al. Green tea extract decreases muscle necrosis in mdx mice and protects against reactive oxygen species. Am J Clin Nutr 2002, 75(4):749-753.
34. Dorchies O.M., Wagner S., Vuadens O., et al. Green tea extract and its major polyphenol (-)-epigallocatechin gallate improve muscle function in a mouse model for Duchenne muscular dystrophy. Am J Physiol Cell Physiol 2006, 290(2):C616-C625.
35. Evans N.P., Call J.A., Bassaganya-Riera J., et al. Green tea extract decreases muscle pathology and NF-kappaB immunostaining in regenerating muscle fibers of mdx mice. Clin Nutr 2010, 29(3):391-398.
36. Anthony J.C., Anthony T.G., Kimball S.R., et al. Orally administered leucine stimulates protein synthesis in skeletal muscle of postabsorptive rats in association with increase eIF4F formation. JNutr 2000, 130:139-145.
37. Nair K.S., Woolf P.D., Welle S.L., et al. Leucine, glucose, and energy metabolism after 3 days of fasting in healthy human subjects. Am J Clin Nutr 1987, 46(4):557-562.
38. Norton L.E., Layman D.K. Leucine regulates translation initiation of protein synthesis in skeletal muscle after exercise. JNutr 2006, 136(2):533S-537S.
39. Lieth E., LaNoue K.F., Berkich D.A., et al. Nitrogen shuttling between neurons and glial cells during glutamate synthesis. JNeurochem 2001, 76(6):1712-1723.
40. Sugawara T., Ito Y., Nishizawa N., et al. Regulation of muscle protein degradation, not synthesis, by dietary leucine in rats fed a protein-deficient diet. Amino Acids 2009, 37(4):609-616.
41. Escobar J., Frank J.W., Suryawan A., et al. Regulation of cardiac and skeletal muscle protein synthesis by individual branched-chain amino acids in neonatal pigs. Am J Physiol Endocrinol Metab 2006, 290:612-621.
42. Escobar J., Frank J.W., Suryawan A., et al. Physiological rise in plasma leucine stimulates muscle protein synthesis in neonatal pigs by enhancing translation initiation factor activation. Am J Physiol Endocrinol Metab 2005, 288(5):E914-E921.
43. Escobar J., Frank J.W., Suryawan A., et al. Amino acid availability and age affect the leucine stimulation of protein synthesis and eIF4F formation in muscle. Am J Physiol Endocrinol Metab 2007, 293(6):E1615-E1621.
44. Mendell J.R., Griggs R.C., Moxley R.T., et al. Clinical investigation in Duchenne muscular dystrophy: IV. Double-blind controlled trial of leucine. Muscle Nerve 1984, 7(7):535-541.
45. D'Antona G., Ragni M., Cardile A., et al. Branched-chain amino acid supplementation promotes survival and supports cardiac and skeletal muscle mitochondrial biogenesis in middle-aged mice. Cell Metab 2010, 12(4):362-372.
46. Anthony J.C., Yoshizawa F., Anthony T.G., et al. Leucine stimulates translation initiation in skeletal muscle of postabsorptive rats via a rapamycin-sensitive pathway. JNutr 2000, 130(10):2413-2419.
47. Buse M.G., Reid S.S. Leucine. A possible regulator of protein turnover in muscle. JClin Invest 1975, 56:1250-1261.
48. Busquets S., Alvarez B., Lopez-Soriano F.J., et al. Branched-chain amino acids: a role in skeletal muscle proteolysis in catabolic states?. JCell Physiol 2002, 191(3):283-289.
49. Fulks R.M., Li J.B., Goldberg A.L. Effects of insulin, glucose, and amino acids on protein turnover in rat diaphragm. JBiol Chem 1975, 250(1):290-298.
50. Hong S.O., Layman D.K. Effects of leucine on invitro protein synthesis and degradation in rat skeletal muscles. JNutr 1984, 114:1204-1212.
51. Nakashima K., Ishida A., Yamazaki M., et al. Leucine suppresses myofibrillar proteolysis by down-regulating ubiquitin-proteasome pathway in chick skeletal muscles. Biochem Biophys Res Commun 2005, 336(2):660-666.
52. Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011, 12(1):21-35.
53. Kim E., Goraksha-Hicks P., Li L., et al. Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol 2008, 10(8):935-945.
54. Sancak Y., Peterson T.R., Shaul Y.D., et al. The Rag GTPases bind raptor andmediate amino acid signaling to mTORC1. Science 2008, 320(5882):1496-1501.
55. Armengol G., Rojo F., Castellvi J., et al. 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res 2007, 67(16):7551-7555.
56. Avruch J., Long X., Ortiz-Vega S., et al. Amino acid regulation of TOR complex 1. Am J Physiol Endocrinol Metab 2009, 296(4):E592-E602.
57. Scott P.H., Brunn G.J., Kohn A.D., et al. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc Natl Acad Sci USA 1998, 95(13):7772-7777.
58. Sparks C.A., Guertin D.A. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 2010, 29(26):3733-3744.
59. Loewith R., Jacinto E., Wullschleger S., et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002, 10(3):457-468.
60. Peterson T.R., Laplante M., Thoreen C.C., et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009, 137(5):873-886.
61. Gan X., Wang J., Su B., et al. Evidence for direct activation of mTORC2 kinase activity by phosphatidylinositol 3,4,5-trisphosphate. JBiol Chem 2011, 286(13):10998-11002.
62. Sarbassov D.D., Ali S.M., Sengupta S., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006, 22(2):159-168.
63. Tremblay F., Brule S., Um S.H., et al. Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc Natl Acad Sci USA 2007, 104:14056-14061.
64. Um S.H., D'Alessio D., Thomas G. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab 2006, 3:393-402.
65. Dobashi Y., Watanabe Y., Miwa C., et al. Mammalian target of rapamycin: a central node of complex signaling cascades. Int J Clin Exp Pathol 2011, 4(5):476-495.
66. Dibble C.C., Asara J.M., Manning B.D. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol 2009, 29(21):5657-5670.
67. Hsu P.P., Kang S.A., Rameseder J., et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 2011, 332(6035):1317-1322.
68. Yu Y., Yoon S.O., Poulogiannis G., et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 2011, 332(6035):1322-1326.
69. Ventrucci G., Mello M.A., Gomes-Marcondes M.C. Effect of a leucine-supplemented diet on body composition changes in pregnant rats bearing Walker 256 tumor. Braz J Med Biol Res 2001, 34(3):333-338.
70. Gomes-Marcondes M.C., Ventrucci G., Toledo M.T., et al. Aleucine-supplemented diet improved protein content of skeletal muscle in young tumor-bearing rats. Braz J Med Biol Res 2003, 36(11):1589-1594.
71. Siddiqui R., Pandya D., Harvey K., et al. Nutrition modulation of cachexia/proteolysis. Nutr Clin Pract 2006, 21(2):155-167.
72. Ventrucci G., Mello M.A., Gomes-Marcondes M.C., et al. Leucine-rich dietalters the eukaryotic translation initiation factors expression in skeletal muscle of tumour-bearing rats. BMC Cancer 2007, 7:42.
73. De Bandt J.P., Cynober L. Therapeutic use of branched-chain amino acids in burn, trauma, and sepsis. JNutr 2006, 136(Suppl 1):308S-313S.
74. Vary T.C., Lynch C.J. Nutrient signaling components controlling protein synthesis in striated muscle. JNutr 2007, 137(8):1835-1843.
75. De Luca A., Pierno S., Liantonio A., et al. Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. JPharmacol Exp Ther 2003, 304(1):453-463.